LPS Flex Porous Femoral Components

Sponsor
Zimmer Biomet (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT01462240
Collaborator
(none)
0
45.4

Study Details

Study Description

Brief Summary

This is a prospective multicenter study of the LPS-Flex Porous Femoral Components when used in primary total knee arthroplasty. The purpose of the study is to obtain short-, mid-, and long-term clinical outcomes and implant survivorship data for the NexGen LPS-Flex Porous Femoral components.

Condition or Disease Intervention/Treatment Phase
  • Device: LPS Flex Porous Femoral Components

Detailed Description

Survival and outcome data on the NexGen LPS-Flex Porous Femoral Components will be done by an analysis of standard scoring system, radiographs and adverse event records. Survivorship will be evaluated by monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated adverse device effects. Outcomes will be measured by comparing the overall pain and function performances (based on the Knee Society Scoring System), survivorship, subject quality of life and radiographic parameters of study subjects receiving the LPS-Flex Porous Femoral Components.

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Prospective Multicenter Post-market Study of the Zimmer NexGen LPS-Flex Porous Femoral Components
Actual Study Start Date :
May 20, 2008
Anticipated Primary Completion Date :
Mar 1, 2012
Actual Study Completion Date :
Mar 1, 2012

Arms and Interventions

Arm Intervention/Treatment
1 - LPS Flex Pororus Femoral Components

Patients suffering from severe knee pain and disability.

Device: LPS Flex Porous Femoral Components
Porous femoral components in total knee arthroplasty

Outcome Measures

Primary Outcome Measures

  1. Survivorship [10 Years]

    Based on frequency of adverse events, serious adverse events, adverse device effects, serious adverse device effects and unanticipated adverse device effects or removal of the device summarized using a Kaplan-Meier method and presented with rates (as percentages) and confidence intervals.

Secondary Outcome Measures

  1. Pain and Functional Performance [10 years]

    Measured by comparing the overall pain and function performances (based on Knee Society Scoring System), survivorship, subject quality of life and radiographic parameters.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient 18-75 years of age, inclusive;

  • Patient qualifies for a total knee arthroplasty based on physical exam and medical history including at least one of the following: rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyle;

  • Post-Traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy;

  • Moderate valgus, varus, or flexion deformities;

  • Patient has undergone a study related informed consent process;

  • Patient is willing and able to provide written consent;

  • Patient is willing and able to cooperate in the required post-operative therapy;

  • Patient is willing and able to complete scheduled follow-up evaluations.

Exclusion Criteria:
  • Patient has previous history of infection in the affected joint and/or a local or systemic infection that could affect the prosthetic joint;

  • Insufficient bone stock on femoral or tibial surfaces;

  • Skeletal immaturity;

  • Neuropathic arthropathy;

  • Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb;

  • Stable, painless arthrodesis in a satisfactory functional position;

  • Severe instability secondary to the absence of collateral ligament integrity;

  • Patient has rheumatoid arthritis and an ulcer of the skin or a history of recurrent breakdown of the skin because of their risk of postoperative infection is greater;

  • Patient has a known sensitivity or allergy to one or more of the implanted materials;

  • Patient is pregnant or considered a member of a protected population (e.g., prisoner, mental incompetence, unable to understand what clinical trial participation entails, etc.)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Zimmer Biomet

Investigators

  • Study Director: Kacy Arnold, RN, MBA, Zimmer Biomet

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zimmer Biomet
ClinicalTrials.gov Identifier:
NCT01462240
Other Study ID Numbers:
  • CMU2010-27K
First Posted:
Oct 31, 2011
Last Update Posted:
Aug 24, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Zimmer Biomet
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2021